Developing Effective Therapeutics to Treat Neurodegenerative Disease






 
RECENT NEWS

 

July 13, 2014:

Drs. Greg Hook, VP Alzheimer’s Research, ALSP, and Vivian Hook, Professor, UCSD and ALSP Scientific Advisor Chair, presented at the American Alzheimer’s International Conference (AAIC) in Copenhagen, Denmark July 12– 17  Read More...



December 4, 2012:

Dr. Michael D. Pierschbacher, CEO, ALSP, announced that Dr. Stephen Jacobsen, Ph.D., joined the ALSP Scientific Advisory Board. Dr. Pierschbacher said “We are honored that
Steve has joined our team. His international stellar reputation for innovation in Alzheimer’s disease drug development and his in-depth unders
tanding of the pharmaceutical industry will help accelerate our program to the clinic.” Read More...

  

October 13-17, 2012: 

Dr. Greg Hook, VP Alzheimer’s Research, ALSP, debuted data on cathepsin B as a target for traumatic brain injury (TBI) and on methods of inhibiting cathepsin B to treat TBI at the Society of Neuroscience meeting in New Orleans, LA, October 13 – 17, 2012 .Read More...

 

September 5, 2012: 

Dr. Michael D. Pierschbacher, CEO, ALSP, announced that Dr. Bernice Wells, MD, MBA, joined the ALSP Board of Directors.  Dr. Pierschbacher said “Bernice is truly an exceptional individual as she has extensive venture capital experience, pharmaceutical industry experience and is a physician.  Her business and technical insight will help insure ALSP succeeds.” Read More...

 

July 16-18, 2012: 

 Drs. Greg Hook, VP Alzheimer’s Research, ALSP, and Vivian Hook, Professor, UCSD and ALSP Scientific Advisor Chair, presented at the American Alzheimer’s International Conference (AAIC) in Vancouver, Canada, July 16 – 18, 2012.  They provided data validating the protease cathepsin B as a key therapeutic target for treating Alzheimer’s disease, and demonstrating the oral efficacy of a cathepsin B inhibitor in an Alzheimer’s disease animal model representative of most Alzheimer’s disease patients. Read More...

 

May 14-15, 2012:  

The National Institute on Aging’s Alzheimer’s Disease Research Summit was held in Bethesda, MD, at which Health and Human Services Secretary Kathleen Sebelius released the ambitious national plan to fight Alzheimer’s disease called the National Alzheimer’s Project (NAPA), which set forth five goals, including the development of an effective treatment for Alzheimer’s disease by 2025.  The meeting called for public comment on how to achieve those goals.  Dr. Greg Hook, VP Alzheimer’s Research, and Dr. Vivian Hook, Professor, UCSD and ALSP Scientific Advisor Chair, attended and participated in the meeting and provided recommendations to NAPA. Read More...

 

April 21 - 25, 2012:

 Dr. Greg Hook of ALSP Inc. and his colleagues Dr. Vivian Hook of UCSD and Dr. Mark Kindy of the Medical University of South Carolina, presented at THE AMERICAN SOCIETY FOR MOLECULAR BIOCHEMISTRY AND MOLECULAR BIOLOGY in San Diego, CA. Read More…

 

To read more about previous ALSP Inc. news and events, please click here.

FOCUSING ON TRAUMATIC BRAIN INJURY (TBI)
 
ALSP Inc. is a privately held company based in San Diego, California, developing small molecule drugs for treating neurodegenerative diseases, initially focused on traumatic brain injury (TBI). 

Each year traffic accidents, falls, assaults, whether military or domestic, and sports injuries account for millions of incidences of traumatic injury to the brain requiring costly treatment in the emergency room and intensive care units with hundreds of thousands requiring hospitalization. These injuries initiate an inflammatory reaction that can cause a lesion in the brain that, depending on severity, often results in lasting brain deficits that can severely impair the productivity and quality of life for the individual sustaining the injury.  These deficits include, but are not limited to, impaired memory, reduced attention span and mental flexibility, an inability to focus mentally, and impaired motor skills.

The financial burden resulting from these injuries ranges into the tens of billions of dollars even though there is as yet no approved drug to treat the condition. We are advancing our proprietary compound, which prevents what is known as the inflammasome from becoming activated, with an eye toward clinical trials for the treatment of TBI. By employing a novel and flexible clinical strategy and a close working relationship with the FDA we anticipate being able to achieve accelerated approval from the FDA to market what has the potential to be the first drug to treat TBI and establish a proof of principle for the applicability of this class of drugs to other forms of neurodegeneration, each of which also has blockbuster potential to treat millions of people. Learn more about our development strategy here.
Each year traffic accidents, falls, assaults, whether military or domestic, and sports injuries account for millions of incidences of traumatic injury to the brain requiring costly treatment in the emergency room and intensive care units with hundreds of thousands requiring hospitalization. These injuries initiate an inflammatory reaction that can cause a lesion in the brain that, depending on severity, often results in lasting brain deficits that can severely impair the productivity and quality of life for the individual sustaining the injury.  These deficits include, but are not limited to, impaired memory, reduced attention span and mental flexibility, an inability to focus mentally, and impaired motor skills.

Inflammation Antagonist for the Treatment of Traumatic Brain Injury (TBI)